[go: up one dir, main page]

EE05235B1 - Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine - Google Patents

Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine

Info

Publication number
EE05235B1
EE05235B1 EEP200000446A EEP200000446A EE05235B1 EE 05235 B1 EE05235 B1 EE 05235B1 EE P200000446 A EEP200000446 A EE P200000446A EE P200000446 A EEP200000446 A EE P200000446A EE 05235 B1 EE05235 B1 EE 05235B1
Authority
EE
Estonia
Prior art keywords
inhibits
receptor
action
composition
treat
Prior art date
Application number
EEP200000446A
Other languages
English (en)
Inventor
L. Browning Jeffrey
Thorbecke Jeanette
Tsiagbe Vincent
Original Assignee
Biogen, Incorporated
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, New York University filed Critical Biogen, Incorporated
Publication of EE200000446A publication Critical patent/EE200000446A/et
Publication of EE05235B1 publication Critical patent/EE05235B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000446A 1998-01-30 1999-01-29 Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine EE05235B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (2)

Publication Number Publication Date
EE200000446A EE200000446A (et) 2001-08-15
EE05235B1 true EE05235B1 (et) 2009-12-15

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000446A EE05235B1 (et) 1998-01-30 1999-01-29 Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine

Country Status (24)

Country Link
EP (1) EP1051187B9 (et)
JP (2) JP4713733B2 (et)
KR (1) KR100622960B1 (et)
CN (1) CN1287853C (et)
AT (1) ATE253930T1 (et)
AU (1) AU752710B2 (et)
BR (1) BR9908214A (et)
CA (1) CA2319698A1 (et)
CZ (1) CZ301026B6 (et)
DE (1) DE69912743T2 (et)
DK (1) DK1051187T3 (et)
EA (1) EA003862B1 (et)
EE (1) EE05235B1 (et)
ES (1) ES2211035T3 (et)
HU (1) HU226044B1 (et)
IL (2) IL137489A0 (et)
IS (1) IS2254B (et)
NO (1) NO328116B1 (et)
NZ (1) NZ506529A (et)
PL (1) PL203279B1 (et)
PT (1) PT1051187E (et)
SK (1) SK285725B6 (et)
TR (2) TR200101693T2 (et)
WO (1) WO1999038525A1 (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313893T3 (es) * 1999-06-28 2009-03-16 ABBOTT GMBH & CO. KG Composicion para la prevencion de crecimiento tumoral.
WO2001058953A2 (en) * 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
PL372239A1 (en) 2002-03-04 2005-07-11 Aton Pharma, Inc. Methods of inducing terminal differentiation
TW200416044A (en) 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
JP2006508645A (ja) * 2002-08-14 2006-03-16 エラスムス ユニバーシティ メディカル センター ロッテルダム 抗癌剤の開発および癌の診断のための、腫瘍の発生に関与することが同定されたマウスゲノム領域の使用
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
PL203279B1 (pl) 2009-09-30
NZ506529A (en) 2002-12-20
HU226044B1 (en) 2008-03-28
IL137489A0 (en) 2001-07-24
EA003862B1 (ru) 2003-10-30
EP1051187B9 (en) 2004-08-11
CZ20002751A3 (cs) 2000-12-13
DK1051187T3 (da) 2004-03-08
DE69912743T2 (de) 2004-09-23
DE69912743D1 (de) 2003-12-18
IS5570A (is) 2000-07-21
SK11302000A3 (sk) 2001-01-18
BR9908214A (pt) 2000-11-28
WO1999038525A1 (en) 1999-08-05
EA200000798A1 (ru) 2001-02-26
NO20003848L (no) 2000-10-02
EP1051187B1 (en) 2003-11-12
HUP0102363A3 (en) 2004-04-28
KR20010040497A (ko) 2001-05-15
AU752710B2 (en) 2002-09-26
NO328116B1 (no) 2009-12-14
CN1289252A (zh) 2001-03-28
IL137489A (en) 2010-05-31
TR200101693T2 (tr) 2002-06-21
CZ301026B6 (cs) 2009-10-14
ATE253930T1 (de) 2003-11-15
CN1287853C (zh) 2006-12-06
TR200002203T2 (tr) 2000-12-21
CA2319698A1 (en) 1999-08-05
ES2211035T3 (es) 2004-07-01
IS2254B (is) 2007-06-15
JP4713733B2 (ja) 2011-06-29
SK285725B6 (sk) 2007-07-06
JP2002501902A (ja) 2002-01-22
HUP0102363A2 (hu) 2001-10-28
HK1029944A1 (en) 2001-04-20
AU2348899A (en) 1999-08-16
EP1051187A1 (en) 2000-11-15
EE200000446A (et) 2001-08-15
KR100622960B1 (ko) 2006-09-12
PT1051187E (pt) 2004-03-31
NO20003848D0 (no) 2000-07-27
PL342063A1 (en) 2001-05-21
JP2010235621A (ja) 2010-10-21

Similar Documents

Publication Publication Date Title
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
PT935465E (pt) Compostos novos de imidazole substituido
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
ECSP088131A (es) Asociación de un agente hipnótico de duración de acción larga y un agente hipnótico de duración de acción corta y su aplicación en terapéutica
NO983189L (no) Nye substituerte imidazolforbindelser
PT957914E (pt) Formulacao de agonistas de 5-ht
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
EE200100243A (et) 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
EE05662B1 (et) Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
TR199900505T2 (et)
SE9802208D0 (sv) Novel compounds
EP1476419A4 (en) N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150129